Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Share Price Falls 3.15% as Large Cap Stock Clears Price-Fall Threshold
- August 21, 2026
- Posted by: Harsh Piplani
- Category: News
Glaxosmithkline Pharmaceuticals Ltd. fell to Rs 2,905.50, down 3.15% today, with a market capitalisation of Rs 51,398.64 crore.
Glaxosmithkline Pharmaceuticals Ltd. Share Price fell to Rs 2,905.50 on 21 August 2026 at 3:03:18 PM IST, down Rs 94.45 or 3.15% from the previous close of Rs 2,999.95. With a market capitalisation of Rs 51,398.64 crore, the stock moved into focus as a large-cap name and a visible top decliner in today’s market update. The supplied data confirms the price fall and shows that the move was large enough to clear the qualifying bar for its market-cap category.
For investors tracking Glaxosmithkline Pharmaceuticals Ltd. Share Price Today, the verified numbers show a weak session from the open through the low. The stock opened at Rs 2,979.25, touched an intraday high of Rs 2,992.55, and then slipped to a day low of Rs 2,903.55 before trading near that lower band. Total traded volume stood at 80,221 shares across exchanges, including 74,754 shares on NSE and 5,467 shares on BSE, while turnover was Rs 1.59 crore.
Why is the stock trending in Stock Market Today searches? The main reason established by the data is the size of the decline itself. The company-specific catalyst is not established by the supplied inputs, but the share price decline, large-cap status and top losers screen placement make it relevant for Glaxosmithkline Pharmaceuticals Ltd. Stock News and broader Share Market Today coverage. In this Univest analysis, the next points to monitor are whether price action stabilises near the day low, how turnover evolves, and how the stock’s scale compares with sector and peer benchmarks.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,905.5 |
| Previous Close | Rs 2,999.95 |
| Today's Change | Rs -94.45 (-3.15%) |
| Day Open | Rs 2,979.25 |
| Day High | Rs 2,992.55 |
| Day Low | Rs 2,903.55 |
| Current Volume (BSE) | 5,467 |
| BSE Traded Volume | 5,467 |
| NSE Traded Volume | 74,754 |
| Combined NSE + BSE Volume | 80,221 |
| Turnover | Rs 1.59 crore |
| Market Capitalisation | Rs 51,398.64 crore |
| Market Cap Category | Large Cap |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) traded at Rs 2,905.5. versus the previous close of Rs 2,999.95, a fall of 3.15%. The stock opened at Rs 2,979.25, reached Rs 2,992.55, touched Rs 2,903.55. Reported volume was 5,467.
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 51,398.64 crore |
Glaxosmithkline Pharmaceuticals Ltd. Fundamental Analysis, based strictly on the supplied data, starts with scale. The company’s market capitalisation stands at Rs 51,398.64 crore, placing it far above the Healthcare sector benchmark median market capitalisation of Rs 132.66 crore and also above the benchmark average of Rs 467.25 crore across 196 companies in the same sector. Even before considering any other ratios, that size difference tells investors they are looking at a significantly larger listed business than most names in the supplied sector set.
That scale is relevant because market capitalisation indicates company size, not valuation comfort or business quality on its own. In Glaxosmithkline Pharmaceuticals Ltd. Stock Analysis terms, the current session’s fall is happening in a company that remains much larger than the benchmark universe used in the sector snapshot. This can matter for how investors interpret day-to-day price action: a 3.15% move in a Rs 51,398.64 crore company draws attention for a different reason than the same percentage move in a smaller stock.
The available dataset does not provide company-specific P/E Ratio, P/B Ratio, EV/EBITDA, ROE, ROCE, EPS, Book Value, Dividend Yield, leverage or cash-flow figures for this company, so the most grounded fundamental context here comes from its market-cap standing and from the valuation and profitability ranges visible across the Healthcare benchmark. Within that sector set, the median P/E is 26.25 and the average is 61.15, with a very wide range from 2.98 to 1614.49. Median P/B is 1.94 and average P/B is 2.58, while median ROE is 11.12 and average ROE is 15.66. Median ROCE is 13.35 and average ROCE is 17.87.
For investors reading Glaxosmithkline Pharmaceuticals Ltd. Financial Results, Glaxosmithkline Pharmaceuticals Ltd. Earnings or Glaxosmithkline Pharmaceuticals Ltd. Fundamental Analysis coverage alongside today’s price fall, the key context is straightforward: the stock is under pressure today, but it belongs to a large market-cap company operating in a sector where valuation and profitability metrics vary widely across constituents. That makes peer and sector positioning especially important, which is where Univest turns next.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Benchmark Median P/E | 26.25x |
| Benchmark Average P/E | 61.15x |
| Benchmark P/E Range | 2.98x to 1,614.49x |
| Benchmark Median P/B | 1.94x |
| Benchmark Median ROE | 11.12% |
| Benchmark Median ROCE | 13.35% |
| Company Market Capitalisation | Rs 51,398.64 crore |
| Benchmark Median Market Cap | Rs 132.66 crore |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) is classified under sector: Healthcare.
Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
The Healthcare sector snapshot shows that today’s decline in this stock is unfolding inside a broad and highly dispersed valuation universe. The benchmark covers 196 companies in the same sector, with wide spreads in P/E, P/B, profitability and market capitalisation, which means context matters more than a single headline move.
Glaxosmithkline Pharmaceuticals Ltd. Market Cap at Rs 51,398.64 crore stands well above every company market-cap figure listed in the benchmark sample range, where the maximum is Rs 2,803.21 crore, the median is Rs 132.66 crore, and the average is Rs 467.25 crore. That does not itself say anything about whether the stock is expensive or inexpensive, but it does underline that the company sits at a much larger scale than the benchmark names shown in the sector snapshot.
Within the Healthcare benchmark, 157 companies contribute to the P/E dataset. The median P/E is 26.25, the average is 61.15, the minimum is 2.98 and the maximum is 1614.49. For P/B, 195 companies are included, with a median of 1.94 and an average of 2.58, ranging from -12.81 to 16.24. Profitability also varies materially: median ROE is 11.12 and average ROE is 15.66 across 195 companies, while median ROCE is 13.35 and average ROCE is 17.87 across the same count.
This matters for Glaxosmithkline Pharmaceuticals Ltd. Share Price News because a 3.15% share price fall in Healthcare cannot be read in isolation from sector structure. The benchmark scope is the same sector, and the company is being watched against a backdrop where profitability and valuation differ sharply across listed peers. In Univest’s reading, the sector data does not establish a direct reason for today’s decline, but it does show that the stock operates within a broad Healthcare and Pharmaceuticals & Drugs landscape where investors regularly compare price action with scale, valuation bands and return metrics.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,803.21 | 50.55 | 1.94 | -0.78 | 8.31 |
| Dishman Carbogen Amcis Ltd. | DCAL | 2,700.59 | 166.73 | 0.41 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,668.21 | 61.53 | 9.73 | 18.65 | 22.17 |
| Solara Active Pharma Sciences Ltd. | SOLARA | 2,653.3 | 0 | 2.41 | 17.23 | 15.34 |
| Hikal Ltd. | HIKAL | 2,644.18 | 0 | 2.2 | 15.22 | 16.15 |
Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) has a market capitalisation of Rs 51,398.64 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
The supplied peer set highlights how unusually large Glaxosmithkline Pharmaceuticals Ltd. is relative to the listed companies shown alongside it. While several peers operate in Pharmaceuticals & Drugs and one in Hospital & Healthcare Services, all of them are substantially smaller on market capitalisation, and their valuation and profitability ratios span a wide range.
On market cap alone, the contrast is stark. Glaxosmithkline Pharmaceuticals Ltd. stands at Rs 51,398.64 crore, while the largest peer in the supplied list, Ind-Swift Laboratories Ltd., is at Rs 2,803.21 crore. Dishman Carbogen Amcis Ltd. is at Rs 2,700.59 crore, Beta Drugs Ltd. at Rs 2,668.21 crore, Solara Active Pharma Sciences Ltd. at Rs 2,653.30 crore, and Hikal Ltd. at Rs 2,644.18 crore. Even the rest of the peer basket remains in a narrow band between Rs 2,356.34 crore and Rs 2,566.23 crore. That means the subject company’s market capitalisation is many times larger than every supplied peer.
The peer valuation and profitability distribution is also broad. P/E values range from 20.29 for Venus Remedies Ltd. to 166.73 for Dishman Carbogen Amcis Ltd., with Ind-Swift Laboratories at 50.55, Beta Drugs at 61.53, Dr Agarwals Eye Hospital at 33.67, Sai Parenteral’s at 142.94, and Fredun Pharmaceuticals at 55.53. P/B ranges from 0.41 for Dishman Carbogen Amcis to 9.73 for Beta Drugs. ROE swings from -2.89 for Dishman Carbogen Amcis and -0.78 for Ind-Swift Laboratories to 36.29 for Dr Agarwals Eye Hospital, while ROCE ranges from -0.26 to 42.40.
For Glaxosmithkline Pharmaceuticals Ltd. Stock Performance watchers, the key peer takeaway is not a simplistic ranking but the breadth of the comparison set. Some peers show stronger reported return ratios, some show weaker profitability, and some trade at notably higher or lower multiples. What clearly stands out is that the company’s scale is materially larger than the peer basket supplied here, so market participants often need to view today’s share price decline through a size-adjusted lens rather than by percentage move alone.
Why Investors Are Watching Glaxosmithkline Pharmaceuticals Ltd.
Investors are watching this stock because the day’s decline was large enough to qualify under the market-cap-based event filter and because the move occurred in a large-cap Healthcare name. Glaxosmithkline Pharmaceuticals Ltd. Share Price Fall searches are likely being driven by the combination of a 3.15% drop, closing-near-low intraday behaviour and visible placement among market movers.
- Verified price action: the stock fell Rs 94.45 to Rs 2,905.50 from a previous close of Rs 2,999.95.
- Intraday structure: it opened at Rs 2,979.25, hit a high of Rs 2,992.55 and a low of Rs 2,903.55, staying near the session low.
- Category threshold:<
- Trading activity: total volume was 80,221 shares, with 74,754 on NSE and 5,467 on BSE; turnover was Rs 1.59 crore.
- Sector positioning: its Rs 51,398.64 crore market capitalisation is far above the Healthcare benchmark median and average.
- Peer context: every supplied peer has a much smaller market capitalisation than the subject company.
What should investors monitor next? In Univest’s view, the immediate markers are whether Glaxosmithkline Pharmaceuticals Ltd. Share Price can move away from the day low, whether turnover expands or cools after this decline, and how future company updates fit against Healthcare sector valuations, profitability ranges and peer positioning. That keeps the focus on verified data rather than speculation.
About Glaxosmithkline Pharmaceuticals Ltd.
Glaxosmithkline Pharmaceuticals Ltd. is being viewed here within the Healthcare sector, and the peer and benchmark data place it alongside companies largely associated with Pharmaceuticals & Drugs, with one benchmark peer from Hospital & Healthcare Services. In market context, that means the stock is followed as part of a broader Indian healthcare and pharma universe where investors compare company size, valuation multiples, profitability measures and trading behaviour.
The supplied benchmark and peer snapshots show that this is a sector with substantial diversity. Some listed names carry moderate P/E multiples, others very high ones. Some peers report negative ROE or ROCE, while others show much stronger return profiles. Market capitalisations in the peer basket are clustered around roughly Rs 2,356 crore to Rs 2,803 crore, whereas Glaxosmithkline Pharmaceuticals Ltd. Market Cap is Rs 51,398.64 crore. That large difference means the company occupies a meaningfully different scale bracket from the benchmark names provided here.
For readers looking at Glaxosmithkline Pharmaceuticals Ltd. Company News, Glaxosmithkline Pharmaceuticals Ltd. Latest News and Glaxosmithkline Pharmaceuticals Ltd. Shareholding Pattern style searches, today’s stock update should be understood first as a price-action event in a large Healthcare company. Univest therefore frames the name as one that belongs to a large-cap segment of the Indian Stock Market while still being compared, for context, against a wide sector set and a smaller listed peer basket.
Track Glaxosmithkline Pharmaceuticals Ltd. Share Price on Univest
Use Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.
Readers tracking Glaxosmithkline Pharmaceuticals Ltd. Share Price, Glaxosmithkline Pharmaceuticals Ltd. Share Price Today and Glaxosmithkline Pharmaceuticals Ltd. Stock News can use Univest to follow live price action, 52-week levels, market capitalisation, sector context and stock analysis in one place. Univest also helps users monitor exchange-wise activity across NSE and BSE, compare peer metrics, and review how a stock is behaving inside screens such as top decliners or other market movers. For anyone following Glaxosmithkline Pharmaceuticals Ltd. Share Price Live, the value lies in combining price updates with broader market insights instead of viewing one session in isolation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the latest Glaxosmithkline Pharmaceuticals Ltd. Share Price today?
Ans. Glaxosmithkline Pharmaceuticals Ltd. Share Price today was Rs 2,905.50 at 3:03:18 PM IST on 21 August 2026. The stock was down Rs 94.45 from the previous close of Rs 2,999.95, making it one of the session’s notable decliners.
Why is Glaxosmithkline Pharmaceuticals Ltd. stock falling today?
Ans. The supplied data confirms that the stock fell 3.15% in the session, but it does not establish a company-specific catalyst. The trend is being tracked because the decline was large enough to qualify under the large-cap price-fall event threshold.
How much did Glaxosmithkline Pharmaceuticals Ltd. Share Price decline today?
Ans. The stock declined by Rs 94.45 or 3.15% during the session. It moved from a previous close of Rs 2,999.95 to Rs 2,905.50, which is why it appeared prominently in top losers and stock updates coverage.
What were the day high, day low and opening price for GLAXO?
Ans. GLAXO opened at Rs 2,979.25, touched a day high of Rs 2,992.55 and fell to a day low of Rs 2,903.55. The last traded price in the supplied data, Rs 2,905.50, remained very close to that intraday low.
<
Ans. Yes. Its actual day change was -3.15%, so the share price decline cleared that exact market-cap-based event threshold.
What was the total trading volume in Glaxosmithkline Pharmaceuticals Ltd. today?
Ans. Total trading volume was 80,221 shares in the supplied snapshot. Of that, NSE accounted for 74,754 shares and BSE accounted for 5,467 shares, while the recorded turnover for the session stood at Rs 1.59 crore.
What is the market capitalisation of Glaxosmithkline Pharmaceuticals Ltd.?
Ans. The company’s market capitalisation is Rs 51,398.64 crore. That places it in the Large Cap category and makes it materially larger than the supplied Healthcare benchmark median market capitalisation of Rs 132.66 crore and average of Rs 467.25 crore.
How does the company compare with the Healthcare sector benchmark on size?
Ans. On the supplied numbers, the company is much larger than the same-sector benchmark universe. Its market capitalisation is Rs 51,398.64 crore versus a benchmark median of Rs 132.66 crore, average of Rs 467.25 crore and maximum of Rs 2,803.21 crore.
Which peers are included in the comparison for this stock?
Ans. The supplied peer basket includes Ind-Swift Laboratories, Dishman Carbogen Amcis, Beta Drugs, Solara Active Pharma Sciences, Hikal, Dr Agarwals Eye Hospital, Panacea Biotec, Sai Parenteral's, Venus Remedies and Fredun Pharmaceuticals within the broader Healthcare space.
Why are investors tracking Glaxosmithkline Pharmaceuticals Ltd. Share Price on Univest?
Ans. Investors are tracking the stock on Univest because it combined a 3.15% price fall with large-cap status, a near-day-low trade at Rs 2,905.50, total volume of 80,221 shares and a clear appearance among important market movers.
